# Curium Acquires Abscint SA to Expand HER2 PET Imaging Pipeline in Oncology

> ma · REPORTED · 2026-08-10

Curium, a global radiopharmaceutical company, completed the acquisition of Belgian clinical-stage company Abscint SA on August 10, 2026, gaining global rights to develop and commercialize ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 currently in a Phase 2b trial. HER2 is a key target in breast and gastric cancers, and the deal strengthens Curium's radiodiagnostic footprint in oncology.

About Curium / Abscint SA: Curium is a global radiopharmaceutical company developing and manufacturing diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology and other disease areas.

- Company: Curium / Abscint SA
- Sector: oncology
- Primary source: https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.